Peanut Oral Immunotherapy Yields Distinct IgE, IgG4 Profiles in Kids After 5 Years

Yamini Virkud, MD, FAAAI, MPH

Credit: UNC Health

At least 5 years after the IMPACT study, children who had undergone peanut oral immunotherapy maintained different allergen-specific IgE and IgG4 profiles than children who had taken placebo.¹ The study is a late-breaker at the 2025 American Academy of Allergy, Asthma, & Immunotherapy (AAAAI) annual meeting in San Diego from February 28 through March 3.

“These findings suggest that the early adoption of peanut [oral immunotherapy has lasting immunologic impact correlating with clinical outcomes,” wrote investigators, led by Yamini Virkud, MD, FAAAI, MPH, from the University of North Carolina, Chapel Hill.

The IMPACT trial demonstrated the success of peanut oral immunotherapy in terms of desensitization, and in some cases, remission, in children 1 – 3 years old.²…